Rna Targeting Therapies For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
| Property |
Value |
| Category |
Gene-Silencing Therapy |
| Target |
mRNA of disease-causing genes |
| Diseases |
Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, FTD |
| Stage |
Preclinical to FDA-Approved |
RNA-targeting therapies represent a revolutionary approach to treating neurodegenerative diseases by directly targeting the messenger RNA (mRNA) that produces toxic proteins. By reducing the production of disease-causing proteins at their source, these therapies offer the potential for disease modification rather than just symptom management.
- Single-stranded DNA analogs that bind to complementary target mRNA
- RNase H-mediated degradation: ASO-RNA hybrid recruits RNase H to cleave the RNA
- Splice-modulating ASOs: Alter RNA splicing to exclude toxic exons
- Steric blockade: Block translation or splicing without degrading mRNA
- Small interfering RNAs (siRNAs): 21-23 nucleotide double-stranded RNAs
- Short hairpin RNAs (shRNAs): Hairpin structures processed into siRNAs
- MicroRNA (miRNA) mimics/antagonists: Modulate endogenous miRNA function
- Argonaute-containing silencing complexes mediate gene silencing
- RNA splice modifiers: Small molecules that modulate splicing
- RNA-binding protein modulators: Target proteins that regulate RNA metabolism
- Ribonucleotide reductase inhibitors: Affect RNA synthesis
¶ Approved and Clinical-Stage Therapies
| Drug |
Target |
Disease |
Approval Year |
| Tofersen |
SOD1 |
ALS |
2023 (accelerated) |
| Nusinersen |
SMN2 |
Spinal Muscular Atrophy |
2016 |
| Inotersen |
TTR |
hATTR Polyneuropathy |
2018 |
| Patisiran |
TTR |
hATTR Polyneuropathy |
2018 |
| Drug |
Target |
Disease |
Phase |
NCT Number |
| ASO-C9orf72 |
C9orf72 |
ALS/FTD |
Phase I/II |
NCT04931862 |
| ASO-GRN |
GRN |
FTD |
Phase I/II |
NCT05547564 |
| ASO-SNCA |
SNCA |
Parkinson's Disease |
Phase I |
NCT04165486 |
| ASO-HTT |
HTT |
Huntington's Disease |
Phase I/II |
NCT05032196 |
| BIIB080 |
MAPT |
Alzheimer's Disease |
Phase I/II |
NCT05399888 |
- SOD1 ASOs (Tofersen): Reduce SOD1 protein in SOD1-linked ALS
- C9orf72 ASOs: Target hexanucleotide repeat expansions
- ATXN2 ASOs: Reduce ataxin-2 levels (ALS risk factor)
- FUS ASOs: Target FUS protein aggregation
- BACE1 ASOs: Reduce BACE1 enzyme to lower Aβ production
- Tau ASOs: Target MAPT mRNA to reduce tau
- APOE ASOs: Target APOE4 allele expression
- SNCA ASOs: Reduce α-synuclein for DLB
- SNCA ASOs: Direct targeting of α-synuclein
- LRRK2 ASOs: Target LRRK2 mutations
- GBA ASOs: Modulate glucocerebrosidase expression
- HTT ASOs: Lower mutant huntingtin protein (several in trials)
- Allele-selective ASOs: Target mutant HTT while sparing wild-type
- Splice-modulating ASOs: Exclude exon 1 to reduce toxic fragments
- GRN ASOs: Reduce progranulin for GRN mutations
- C9orf72 ASOs: Target repeat expansions
- MAPT ASOs: Reduce tau for CBD/PSP
- Intrathecal delivery: Direct to CSF (used for nusinersen, tofersen)
- Conjugated ASOs: Using receptor-mediated transcytosis
- AAV-delivered RNAi: Gene therapy approach
- Intranasal delivery: Non-invasive alternative
- Naked ASOs: Rely on endocytosis
- Conjugated ASOs: Enhance cellular entry
- Formulation with lipids: Improve delivery
- Viral vectors: For shRNA/miRNA delivery
- Injection site reactions (for intrathecal delivery)
- Thrombocytopenia
- Liver enzyme elevations
- Kidney toxicity
- CSF pleocytosis (mild inflammation)
- Off-target effects: Unintended gene silencing
- Immune activation: Cytokine responses to dsRNA
- Delivery-related: Inflammation at injection site
- Allele-Selective Therapy: Targeting mutant allele while sparing wild-type
- Motor Neuron-Targeting: Improving delivery to motor neurons
- Combination Approaches: ASO + small molecule combinations
- Biomarkers: Developing PK/PD markers for clinical trials
- Repeat-Expansion Targeting: Beyond C9orf72 (SCA, HD)
- Non-Viral Delivery: Safer than viral vectors
The study of Rna Targeting Therapies For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
[1] Miller T, et al. Phase 1-2 trial of tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109-119.
-
[2] Tabrizi SJ, et al. Targeting huntingtin for Huntington's disease. Nat Rev Drug Discov. 2019;18(9):705-719.
-
[3] Benn CL, et al. ASO approaches for neurodegenerative diseases. Brain. 2021;144(8):2274-2293.
-
[4] Nguyen L, et al. RNA-targeting therapies for ALS and FTD. Nat Rev Neurol. 2023;19(1):31-44.
-
[5] Southwell AL, et al. Huntingtin lowering for Huntington's disease. Nat Rev Neurol. 2022;18(12):705-719.
-
[6] Swayze EE, et al. Antisense oligonucleotides targeting disease-associated proteins. Nucleic Acid Ther. 2022;32(3):109-125.
-
[7] Bhattacharya K, et al. siRNA delivery to the brain: progress and challenges. J Control Release. 2021;337:456-471.
-
[8] Khvorova A, et al. RNA targeting in neurological disease. Cell. 2024;187(1):23-42.